maintain market outperform rate lower price target reflect increas risk
incyt corpor mo pt bayko merck nc
announc extern dmc review pivot phase
studi result evalu epacadostat combin
keytruda pembrolizumab patient unresect metastat
melanoma determin studi meet primari endpoint
improv overal popul compar keytruda monotherapi
reiter market outperform rate lower
price target base dcf sotp valuat
methodolog rais discount rate lower dcf valuat
per share sotp valuat per share failur could
lower expect cala collabor includ
combin put pressur
share opinion
plan stop studi base
recommend dmc
recal enter global collabor
develop commerci arginas inhibitor januari
see note current studi
monotherapi combin pembrolizumab phase i/ii trial enrol
patient advanc solid tumor nsclc melanoma urotheli cell carcinoma
colorect cancer gastroesophag cancer hnscc mesothelioma
compani also said enrol phase i/ii trial evalu
combin chemotherapi initi novemb epacadostat
epacadostat/pembrolizumab expect begin
failur
increas risk
tripl combin provid
benefit pembrolizumab alon metastat melanoma
epacadostat metabol modul meant reduc
immunosuppress effect arginas ido respect tumor
microenviron vari significantli across tumor type earli clinic data
shown increas plasma arginin activ t-cell
nk cell support idea compound could enhanc pembrolizumab
efficaci regardless ido activ
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
remain bullish though lower price target account
percept increas clinic risk stori calithera clinical-stag
oncology-focus drug discoveri develop compani exploit new discoveri
target cancer growth enhanc
therapeut compani first product candid novel inhibitor
glutaminas enzym convert glutamin glutam latter critic
feedstock cell energi product system addit cala arginas inhibitor cb-
demonstr capac revers immunosuppress effect enzym
tumor microenviron subject valid collabor
mo pt bayko compani found susan chri molineaux two
main founder proteolix compani develop kyproli carfilzomib
eventu sold onyx onyx pharmaceut turn sold amgen
nc billion
figur synthesi valuat approach
synthesi valuat approachesapproachweightvaluationdcf discount sale us- rcc us- tnbc us ex-u royalties- global nsclc royalties- global melanoma royalties- total revenu product sales- gross profit- sg total oper oper incom oper margin tax oper residu valu cash termin long-term debt dilut share outstand growth inc
jmp secur llc compani report
sum-of-the-part analysisvalu mm per discount rate dev stagedisc rateest us tnbcph melanomaph blend discount phase i/ii trial solid tumor combin phase ii cantata studi combin cabozantinib everolimu cabozantinib combin data rcc phase ii nivolumab combin data phase ii paclitaxel combin datat new pipelin candid figur incom statement
jmp secur llc compani report
statement sale sales- row royalties- royalties- total product sale royalties- collabor revenue- total revenue- good sold- gross profit- oper expens research oper oper incom loss margin expensetot incom net pre-tax incom tax benefit incom ep common dilut ep common inc inc
base san francisco ca clinical-stag biotechnolog compani focus discoveri develop
novel small molecul direct cancer immun cell metabol treat solid tumor hematolog malign
compani lead product candid intern discov wholly-own potent oral select inhibitor glutaminas
inhibit glutaminas effect starv cancer cell glutam critic substrat cancer cell metabol growth
surviv current phase ii trial set rcc tnbc melanoma compani first-in-class arginas inhibitor
demonstr capac revers immunosuppress effect enzym tumor microenviron
subject valid collabor incyt corpor
potenti risk invest thesi valuat includ limit clinic regulatori commerci competit financi
scientif clinic drug develop inher riski busi cancer metabol specif role glutaminas
cancer pathogenesi remain larg unproven creat signific risk associ calithera scientif platform like clinic trial
clinic develop carri risk failur may fail maintain requisit safeti
demonstr meaning efficaci warrant develop regulatori approv
regulatori commerci abil calithera potenti partner market drug depend drug obtain approv
fda foreign regulatori agenc failur achiev approv delay timelin approv could neg impact
competit oncolog drug develop increasingli competit field calithera face competit compani develop small-
molecul therapi also direct cancer cell metabol way may resembl calithera pipelin small-molecul oncolog
therapi employ mechan action also develop sever biopharma compani treat similar patient popul
may yield superior risk/benefit outcom compani may access greater resourc
develop commerci expertis compar calithera
anticip calithera may seek addit equiti financ form secondari offer complet develop
advanc futur pipelin candid expos exist sharehold degre dilut risk
